Facebook
Twitter
LinkedIn
Forward
Deep Dive on Lung Cancer Stage III and IV
This is an educational course - a deeper dive on Lung Cancer and it includes video, slides, and audio files from the following sessions presented in 2021:
- Lung Cancer: Learning from the past, focusing on the future, treating in the present
- Overcoming Barriers to Care - Diagnosis and Referrals
- Best Practices for the Continuum of Care, a Multidisciplinary Approach
- Continuum of Care for Nonresectable Non-Small Cell Lung Cancer - Challenging Cases
- Lung Cancer Case Based Discussion Stage III Case-based Approach
- Novel Radiotherapy Approaches in Stage IV NSCLC
This activity is available from December 1, 2021, through 11:59 p.m. Eastern time on November 30, 2024.
These activities were originally recorded during:
- ASTRO's 2021 Annual Refresher Course, March 19-21, 2021
- ASTRO Annual Meeting, October 24-27, 2021
- Separate webinars in 2021.
Course instructions can be accessed through the Program tab.
Target Audience
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, nurses, pathologists, internists, family practitioners, radiation therapists and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, learners should be able to do the following per course:
- Apply the increasing role of radiotherapy in advance stage lung cancer.
- Order appropriate staging assessments and other necessary workup to allow timely initiation of treatment.
- Discuss decision making for concurrent chemotherapy.
- Discuss considerations for safe radiotherapy delivery.
- Explain best practice in the use of stereotactic ablative body radiation for treatment of early stage lung cancer; analyze how to approach challenging situations such as central tumors.
- Identify optimal patient selection and treatment planning techniques for challenging scenarios for SABR.
- Apply latest data regarding treatment of locally advanced NSCLC.
- Identify patients with Stage IV NSCLC who may benefit from consolidative thoracic radiotherapy.
- Explain rationale for aggressive treatment of patients with oligometastatic NSCLC.
- Discuss risks of combining radiation therapy with novel systemic therapies in the treatment of Stage IV NSCLC.
PROGRAM INSTRUCTIONS:
Registration:
Click on the Register tab in the course navigation. Scroll down to add the Deep Dive on Lung Cancer Stage III and IV course to your cart. All courses listed are included with your purchase.
Navigation:
To begin:
- Click on the Take Course tab in the course navigation to see the list of included sessions.
- Click on the title of the course you would like to view.
- Once in the course, review the overview, objectives, and faculty details before clicking Take Course to begin viewing the content.
- Use the left course progress bar to navigate the course or the green buttons in the course navigation bar at the bottom.
- You may view the courses in any order and as many or as few as you wish to receive credit(s).
Once you have completed each course, you can return to the list of courses available by clicking on Return to Deep Dive on Lung Cancer Stage III and IV Course.
Repeat the above steps to complete as many courses as you wish to view. You may return later to complete or review any of the courses.
Note: To re-enter the course, you will find it in your Completed Activities tab.
Go to the Take Course tab to re-access. Courses that have been viewed/completed will have a checked circle and non-viewed courses will say Enrolled. You can view courses as many times as you would like.
Certificates/Credits
You may view and claim credit for some or all of the courses. Each time you complete the viewing and evaluation of a course, your CME certificate for the course will update with the new credit hours awarded.
Below is the faculty and their disclosures for all courses.
| Name | Employment | Compensation/Remuneration/Funding | Ownership Investment Interests | Leadership Position |
| Kate Aldridge, CMD, RT | Henry Ford Health System: CMD | None | None | None |
| Christine Bestvina, MD | Northwestern Medicine: Instructor of Medicine: Employee University of Chicago: Assistant Professor: Employee | Abbvie: Consultant: Advisory Board AstraZeneca, Genentech, Pfizer, Seattle Genetics, Takeda: Consultant: Advisory Board | None | None |
| Aileen Chen, MD | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX: | None | None | None |
| Megan Daly, MD | University of California, Davis: Associate Professor | NIH: Research Department of Defense: Research American Cancer Society: Research EMD Serono: Research Boston Scientific: Advisory Board Triptych Health Partners: Consultant Genentech: Research Merck: Research | None | IJROBP: Associate Editor Practical Radiation Oncology: Executive Editor Seminars in Oncology: Editorial Board Member |
| Russell Hales, MD | Johns Hopkins University: Faculty | None | None | None |
| Puneeth Iyengar, MD | UT Southwestern Med Center: Assistant Professor: Employee | AZ: Advisory Boards | None | None |
| Gregory Kalemkarian, MD | University of Michigan | Merck: Research Takeda: Research Blueprint: Research Daiichi-Sankyo: Research Cullinan: Research | None | None |
| Florence K. Keane, MD | Partners Healthcare: Physician: Employee | AstraZeneca: Advisory Board OncLive: Speaker's Bureau | None | None |
| Martha Matuszak, Phd | University of Michigan | Varian Medical Systems: Research, Consultant | None | Michigan Radiation Oncology Quality Consortium: Co-director and Physics lead |
| Michael Offin, MD | Memorial Sloan Kettering Cancer Center: Assistant Attending | PharmaMar: Honoraria Novartis: Honoraria Targeted Oncology: Honoraria Jazz Pharmaceuticals: Honoraria OncLive: Honoraria | None | None |
| Dawn Owen, MD, PhD | Mayo Clinic Rochester: Physician | Up to Date: Honoraria Mayo Clinic: Research | None | None |
| Bradford Perez, MD | H Lee Moffitt Cancer Center: Associate Member: Employee | BMS: Research Grants | None | None |
| Chinh Phan, DO | UC Davis Health: Assistant Clinical Professor | None | None | None |
| Janani Reisenauer, MD | May Clinic: Physican | Intuitive Surgical: Research Elucent Medical Surgical Navigation: Advisory Board AstraZeneca: Honoraria Siemens: Honoraria | None | None |
| Jacob Sands, MD | Dana Farber Cancer Institute | AstraZeneca: Travel, Consultant, Advisory Board Blueprint Medicines: Consultant, Advisory Board Boehringer Ingelheim: Consultant Advisory Board Daiichi Sankyo/UCB Japan: Consultant, Advisory Board Foundation Medicine: Consultant, Advisory Board Guardant Health: Consultant, Advisory Board Jazz Pharmaceuticals: Consultant, Advisory Board Lilly: Consultant, Advisory Board Medtronic: Consultant, Advisory Board PharmaMar: Consultant, Advisory Board Takeda: Consultant, Advisory Board | None | None |
| Anand Shivnani, MD | Texas Oncology, McKinney, TX: Employee | None | Gradalis | None |
| Michael Simoff, MD | Henry Ford Health System: Senior Staff Physician | Varian Medical Systems: Advisory Board Intuitive Surgical: Consultant, Travel Expenses Gongwin BioPharm: Research, Consultant | None | None |
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 7.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 7.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 7.00 Certificate of AttendanceThis activity was designated for 7.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $150
- Member: $99
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.